Startups
AI drug development startup Pathos AI closes $237M investment
AI drug development startup Pathos AI raises $237 million in Series E funding at a $3 billion valuation, led by Bristol Myers Squibb.
Topic
#Drug Development
Stories tagged by our AI curator.
AI
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
Pathos AI collaborates with Bristol Myers Squibb and Tempus AI to develop AI tools for Alzheimer's drug development.
AI
Claude did not invent scorpion antivenom
An experiment by Citrini Research and Anthropic attempting to use Claude AI to develop scorpion antivenom failed, with the model providing only preliminary suggestions rather than functional drug designs.